Wedbush downgrades Foghorn Therapeutics to Neutral, sets price target to $2
Wedbush downgraded Foghorn Therapeutics's stock to Neutral with a price target of $2.00, implying a downside of 31.5% from the Oct 1 close of $2.92.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.